News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alfresa Pharma, AnGes MG Inc. Sign Joint Development Contract For Atopic Dermatitis Drug


10/19/2005 5:09:29 PM

Tokyo (JCNN) - Alfresa Holdings (TSE: 2784) announced on July 8 that its wholly owned subsidiary Alfresa Pharma has signed a contract with AnGes MG (TSE: 4563) for the development of atopic dermatitis drug using NF-kappa B decoy oligodeoxynucleotide, a type of nucleic acid drug that AnGes MG is developing with the aim of developing applications in atopic dermatitis and rheumatic arthritis.

Read at JCN Newswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES